Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells

Blood Cancer Journal

Volumn 3, Issue 5, 2013, Pages

  Abdi, J ^a   Mutis, T ^b   Garssen, J ^a   Redegeld, F ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apoptosis; Fibronectin; Multiple myeloma; Pam3CSK4; Toll like receptor; Velcade

Indexed keywords

BORTEZOMIB; CASPASE 3; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROCASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN P73; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG RESISTANCE; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84878316176     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.17     Document Type: Article

References (51)

1. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995-5004.
2. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007; 1775: 163-180.
3. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002; 71: 495-502.
4. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012; 2012: 283181.
5. Cordes N. Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury. Cancer Lett 2006; 242: 11-19.
6. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
7. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
8. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69: 1009-1015.
9. Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F et al. alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 2001; 29: 993-1003.
10. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Alpha(v)-beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002; 87: 836-845.
11. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231-242.
12. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
13. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38: 71-81.
14. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol 2000; 12: 557-563.
15. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319-4327.
16. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519-2526.
17. Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2009; 2: 649-662.
18. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A et al. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005; 90: 479-488.
19. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
20. Salaun B, Romero P, Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007; 37: 3311-3318.
21. Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia 2006; 20: 937-938.
22. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304.
23. Chiron D, Jego G, Pellat-Deuceunynck C. Toll-like receptors: expression and involvement in multiple myeloma. Leuk Res 2010; 34: 1545-1550.
24. Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol 2009; 182: 4471-4478.
25. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogenassociated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20: 1130-1137.
26. Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L, Borset M et al. Tolllike receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20: 1138-1144.
27. Xu Y, Zhao Y, Huang H, Chen G, Wu X, Wang Y et al. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol 2010; 150: 543-553.
28. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008; 112: 2205-2213.
29. Ueda S, Nakamura H, Masutani H, Sasada T, Yonehara S, Takabayashi A et al. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol 1998; 161: 6689-6695.
30. Abdi J, Engels F, Garssen J, Redegeld FA. Toll-like receptor-9 triggering modulates expression of alpha-4 integrin on human B lymphocytes and their adhesion to extracellular matrix proteins. Exp Hematol 2011; 39: 927-933.
31. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic antimyeloma activity. Cancer Biol Ther 2010; 9: 936-944.
32. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 2001; 8: 1131-1135.
33. de Heer P, de Bruin EC, Klein-Kranenbarg E, Aalbers RI, Marijnen CA, Putter H et al. Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res 2007; 13: 5810-5815.
34. Puszynski K, Bertolusso R, Lipniacki T. Crosstalk between p53 and nuclear factor-B systems: pro-and anti-apoptotic functions of NF-B. IET Syst Biol 2009; 3: 356-367.
35. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M et al. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 2010; 29: 2795-2806.
36. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13: 460-469.
37. Kagawa K, Inoue T, Tokino T, Nakamura Y, Akiyama T. Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. Biochem Biophys Res Commun 1997; 241: 481-485.
38. Kimura Y, Furuhata T, Shiratsuchi T, Nishimori H, Hirata K, Nakamura Y et al. GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene 1997; 15: 1369-1374.
39. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004; 95: 7-11.
40. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M et al. Aberrant methylation of Reprimo in human malignancies. Int J Cancer 2005; 115: 503-510.
41. Xenaki G, Ontikatze T, Rajendran R, Stratford IJ, Dive C, Krstic-Demonacos M et al. PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 2008; 27: 5785-5796.
42. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 2002; 277: 30838-30843.
43. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
44. Zhivotovsky B, Kroemer G. Apoptosis and genomic instability. Nat Rev Mol Cell Biol 2004; 5: 752-762.
45. Voss OH, Kim S, Wewers MD, Doseff AI. Regulation of monocyte apoptosis by the protein kinase C delta-dependent phosphorylation of caspase-3. J Biol Chem 2005; 280: 17371-17379.
46. Tang CH, Hsu CJ, Fong YC. The CCL5/CCR5 axis promotes interleukin-6 production in human synovial fibroblasts. Arthritis Rheum 2010; 62: 3615-3624.
47. Zeigler MM, Doseff AI, Galloway MF, Opalek JM, Nowicki PT, Zweier JL et al. Presentation of nitric oxide regulates monocyte survival through effects on caspase-9 and caspase-3 activation. J Biol Chem 2003; 278: 12894-12902.
48. Tang CH, Hsu CJ, Yang WH, Fong YC. Lipoteichoic acid enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, PKCdelta and c-Src dependent pathways. Biochem Pharmacol 2010; 79: 1648-1657.
49. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 1997; 272: 20131-20138.
50. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003; 278: 32507-32516.
51. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood 2010; 115: 61-70.